Literature DB >> 16682197

Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease.

Hiromi Naka1, Kenta Teruya, Jeong Kyu Bang, Saburo Aimoto, Tadashi Tatsumi, Hiroyuki Konno, Kazuto Nosaka, Kenichi Akaji.   

Abstract

Core sequences necessary for substrate recognition and its inhibition at the PR/p3 site of HTLV-1 protease were clarified for the first time. From the cleavage rates of peptides containing a part of the PR/p3 site, a heptapeptide was found to be the minimal sequence required for substrate recognition. The use of synthetic inhibitors containing hydroxyethylamine dipeptide isostere indicated that a tetrapeptide sequence was necessary to achieve potent inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682197     DOI: 10.1016/j.bmcl.2006.04.056

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Design of new potent HTLV-1 protease inhibitors: in silico study.

Authors:  Mitra Kheirabadi; Javad Maleki; Safieh Soufian; Samaneh Hosseini
Journal:  Mol Biol Res Commun       Date:  2016-03

Review 2.  Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.

Authors:  Michael D Lairmore; Rajaneesh Anupam; Nadine Bowden; Robyn Haines; Rashade A H Haynes; Lee Ratner; Patrick L Green
Journal:  Viruses       Date:  2011-07-12       Impact factor: 5.048

3.  The Effects of Side-Chain Configurations of a Retro-Inverso-Type Inhibitor on the Human T-Cell Leukemia Virus (HTLV)-1 Protease.

Authors:  Chiyuki Awahara; Daiki Oku; Saki Furuta; Kazuya Kobayashi; Kenta Teruya; Kenichi Akaji; Yasunao Hattori
Journal:  Molecules       Date:  2022-03-02       Impact factor: 4.411

4.  Inhibiting HTLV-1 Protease: A Viable Antiviral Target.

Authors:  Gordon J Lockbaum; Mina Henes; Nathaniel Talledge; Linah N Rusere; Klajdi Kosovrasti; Ellen A Nalivaika; Mohan Somasundaran; Akbar Ali; Louis M Mansky; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2021-02-23       Impact factor: 5.100

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.